CRISPR Therapeutics AG (CRSP) Receivables - Net (2015 - 2024)

CRISPR Therapeutics AG has disclosed Receivables - Net across 10 years of filings, most recently posting $25.0 million for Q4 2024.

• In Q4 2024, Receivables - Net fell 87.5% year-over-year to $25.0 million; the TTM figure through Dec 2024 stood at $25.0 million (down 87.5% YoY), while the FY2024 annual figure was $25.0 million, down 87.5% from the prior year.
• Receivables - Net came in at $25.0 million for Q4 2024 at CRISPR Therapeutics AG, down from $200.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $200.0 million in Q4 2023 to a low of $33000.0 in Q2 2020.
• Average Receivables - Net over 5 years is $23.0 million, with a median of $150000.0 recorded in 2021.
• Year-over-year, Receivables - Net sank 99.4% in 2021 and surged 105960.61% in 2023.
• Over 5 years, Receivables - Net stood at $144000.0 in 2020, then surged by 111.81% to $305000.0 in 2021, then slumped by 83.93% to $49000.0 in 2022, then jumped by 408063.27% to $200.0 million in 2023, then sank by 87.5% to $25.0 million in 2024.
• Per Business Quant data, the three most recent Receivables - Net figures were $25.0 million in Q4 2024, $200.0 million in Q4 2023, and $70.0 million in Q2 2023.